Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT05458258 Recruiting - Clinical trials for Acute Myeloid Leukemia

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

Start date: March 1, 2023
Phase:
Study type: Observational

This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will receive induction chemotherapy (chemotherapy given as the first treatment to help cancer go into remission) and/or cancer drugs as part of standard care for AML. By studying how these nutritional and skeletal factors, doctors leading this study hope to learn how malnutrition and sarcopenia may be able to predict certain outcomes --such as how long study participants with poor nutrition and muscle loss can live after chemotherapy- for older (age 60+) individuals with AML.

NCT ID: NCT05457010 Recruiting - Clinical trials for Acute Myeloid Leukemia

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Start date: November 28, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

NCT ID: NCT05456191 Recruiting - Clinical trials for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

ASC4START
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).

NCT ID: NCT05455294 Recruiting - Clinical trials for Acute Myeloid Leukemia

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: - Venetoclax - Decitabine - Navitoclax

NCT ID: NCT05453903 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Start date: October 4, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).

NCT ID: NCT05449899 Recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Start date: July 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Allo-HSCT is the most effective way to cure sAML patients. At present, the best conditioning regimen for sAML patients undergoing allo-HSCT remains in discussion. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in sAML patients undergoing allo-HSCT are evaluated.

NCT ID: NCT05448599 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Start date: July 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.

NCT ID: NCT05445154 Recruiting - Clinical trials for Newly Diagnosed Acute Myeloid Leukemia (AML)

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Start date: August 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to describe the dose limiting toxicities (DLT) of SKLB1028 when combined with cytarabine/ daunorubicin remission induction in a 7+3 schedule. Safety and tolerability of SKLB1028 will also be evaluated. This study will also characterize the pharmacokinetics (PK) of SKLB1028 when given in combination with cytarabine/daunorubicin remission induction and high-dose cytarabine (HiDAC) consolidation therapy in newly diagnosed acute myeloid leukemia .

NCT ID: NCT05445011 Recruiting - Clinical trials for Acute Myeloid Leukemia

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Start date: June 14, 2022
Phase: Phase 1
Study type: Interventional

This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute myeloid leukemia.

NCT ID: NCT05442580 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

CART-38 in Adult AML and MM Patients

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".